Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.
Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.
复制标题
DOI：
10.1007/s12016-020-08796-4
复制
发表时间：
2021-04
影响因子：
9.1
通讯作者：
Giri S
中科院分区：
文献类型：
--
作者：
Zahoor I;Giri S
多发性硬化症（MS）是一种神经炎性疾病，其中未解决的和不受控制的炎症破坏正常的细胞稳态并导致病理性疾病状态。长期以来，人们已经认识到ω脂肪酸的内源性衍生的代谢副产物，称为专门的促分解脂质介质（SPM），有助于解决病理性炎症。然而，尽管MS是一种经典的慢性炎症模型，但关于MS中SPM的功能状态的数据很少。迄今为止的研究表明，SPM生物合成途径的功能障碍是导致其在患者来源的生物流体中水平改变的原因，这导致炎症和疾病严重程度增加。总的来说，目前的研究结果表明，由于迄今为止进行的研究中生物基质的结果不同，SPM在MS中的作用存在争议，这也可能部分归因于人群特征的差异。似乎SPM通过在其临床前模型中对脑小胶质细胞施加促分解作用而对MS具有神经保护作用;然而，没有报告表明SPM对少突胶质细胞或神经元的直接作用。这表明，“一种尺寸不适合所有”的概念在其他炎症条件下SPM的状态方面对MS具有重要意义。缺乏明确性是这次审查的动力，这是第一次总结有关SPM在MS中作用的相关数据，以及将其作为生物标志物开发和未来替代疗法的潜力。了解SPM作为消退介质的生物学作用背后的机制可能会预防甚至治愈MS和其他神经退行性病变。
Multiple sclerosis (MS) is a neuroinflammatory disease in which unresolved and uncontrolled inflammation disrupts normal cellular homeostasis and leads to a pathological disease state. It has long been recognized that endogenously derived metabolic by-products of omega fatty acids, known as specialized pro-resolving lipid mediators (SPMs), are instrumental in resolving the pathologic inflammation. However, there is minimal data available on the functional status of SPMs in MS, despite the fact that MS presents a classical model of chronic inflammation. Studies to date indicate that dysfunction of the SPM biosynthetic pathway is responsible for their altered levels in patient-derived biofluids, which contributes to heightened inflammation and disease severity. Collectively, current findings suggest the contentious role of SPMs in MS due to variable outcomes in biological matrices across studies conducted so far, which could, in part, also be attributed to differences in population characteristics. It seems that SPMs have neuroprotective action on MS by exerting proresolving effects on brain microglia in its preclinical model; however, there are no reports demonstrating the direct effect of SPMs on oligodendrocytes or neurons. This reveals that “one size does not fit all” notion holds significance for MS in terms of the status of SPMs in other inflammatory conditions. The lack of clarity served as the impetus for this review, which is the first of its kind to summarize the relevant data regarding the role of SPMs in MS and the potential to target them for biomarker development and future alternative therapies for this disease. Understanding the mechanisms behind biological actions of SPMs as resolution mediators may prevent or even cure MS and other neurodegenerative pathologies.
登录
查看更多内容
DOI：
10.1177/1352458515578770
发表时间：
2015-12
期刊：
Multiple sclerosis (Houndmills, Basingstoke, England)
影响因子：
--
作者：
Cortese M;Riise T;Bjørnevik K;Holmøy T;Kampman MT;Magalhaes S;Pugliatti M;Wolfson C;Myhr KM
通讯作者：
Myhr KM
影响因子：
--
作者：
Chari DM
通讯作者：
Chari DM
DOI：
10.1177/1352458517691150
发表时间：
2017-12
期刊：
Multiple sclerosis (Houndmills, Basingstoke, England)
影响因子：
--
作者：
Bjørnevik K;Chitnis T;Ascherio A;Munger KL
通讯作者：
Munger KL
影响因子：
5.8
作者：
Bjornevik, Kjetil;Myhr, Kjell-Morten;Torkildsen, Oivind
通讯作者：
Torkildsen, Oivind
影响因子：
4
作者：
Briggs, Farren B. S.;Yu, Justin C.;Ontaneda, Daniel
通讯作者：
Ontaneda, Daniel